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Antiarrhylhmic drugs prolong the e~Teellve refractory period and 
depress conduction. To determine the exact role played by there 
two eletlrophysialogir elkis in iiw termination ol reentry, Ihe 
ctfectr of disopyramide, Recsinide, propsfcnone and E.4031, a 
new class III drug, we examined in a canine m&l or nlrial 
flutter lcycle length 120 t 4 to 131 !x 3 mrl caused by reentry. 
Atrial flutter WE induced in32 anerthetited open chest dqs after 
placement of au intercwal crush. The excitable gap ranged from 
9 2 2% to II f 4% of the basic flutter cycle Ienglh, The effective 
refractory period in the rernirant circuit during atria1 Rulter was 
esiimated by sublracting the excitable gap from the hnsic flutter 
cycle length. 
Prolongation of Ratter cycle lengih hg Ihe test drugs was 
pmpariional 10 the inleratritd conduclion lime (r = 0.87, p < 
0.001). Atrial flutter was terminated by each test drug in all dogs 
A variety ofclinical tachyarrhythmias are believed ID be due 
IO reemry with an excitable gap. These arrhythmias include 
atria.1 Aulter (I.21 and sustained monomorphic ventricular 
tachycardia in patients with prior myocardial infarction 
13.1! Althuugh antiarrhythmic drugs crm interrupt the reen- 
try of these arrhythmias. the precise mechanisms hsvc not 
been clarified. Some invesligators (S) have stressed the 
prolongation of refractoriness. Slowing of conduction might 
neutralize the effect of prolongation of the effective refrar 
tory period to inlcrrupi reentry. We hypothesized that a 
clab~ Ill drug would interrupt reentry by abolishing the 
excitable gap through prolongation of Ihc rekactory period. 
whereas a class IC drug would do so by suppressing con- 
duch 10 a crucial point beyond which propagation of 
conduction would become Impossible. 
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except for Rerainide and pmpabnone in one dog each. E4OJI 
prolongd the relraetory @xl during airisl flutter to 129 5 
6 ms, which did nol differ rignificantly from the flutter cyclelength 
immediately before lermination (134 f 4 ms). The refractary 
pried during atria1 flutter after injeclion of the other drugs was 
shorter than the flutter cycle Ia@ before termination of atrlal 
Butter Wxexample, Recainide 124 f 5 vs. 179 * II ms, p < 0.01). 
There data indicate lhat E4031 terminated atrial Butter by 
abolishing the excitable gap lhrough a greater prolangaiion af 
refracloriness relative to a lerserslowingofconduction. The other 
drugs interrupted atria1 flutter by supprralng conduction to a 
crucial point beyond which propagation of conduclion became 
impoaible. 
(J Am Cell Cardial 1991;18:109&104) 
To test this hypothesis. we investigated the effects of 
disopyramide (clahs IAI. Recainide (class ICI. propafenone 
(class ICI and E-4031. a new class 111 drug 16.7). on the 
excitable gap. rcfrac~ory period and conduction in a canine 
model of atrial flutter caused by reentry (I). Disopyramide 
181. Recainide (9.10) and propafenone 1 t1.12) were selected 
because of their efficacy in the treatmenl of clinical atrial 
flutter. Our results were different from those of a previous 
study (13). 
Methods 
All experiments were performed in accordance with the 
“Guide for Animal Experimentation” at the Faculty of 
Medicine of University of Tukyo. 
Surgical procedures. Atdal flutter due to reentry was 
induced as reported elsewhere (1.14). Briefly, 32 mongrel 
dogs were anesthetized with sodium pentobarbital(30 &kg 
body weight intravenously) and intubated with a tracheal 
tube. The heart was exposed through a right thoracotomy in 
the founh intercostal space under artificial respiration with a 
volume-cycled respir;ltor. An anatomic obstacle was pro- 
duced by intercaval crush 115). 
Three bipolar hook electrodes were placed in the right 
atrium and another three in the left atrium to record atrial 
5gure 1. Diagram of the expetimcntal method. Atria are wn from 
the back, and intercaval crush is indicawd between the iuperwr 
(WC) and inferior (IVC) venae cavae. Numbers indicate rhr We 
and numbers of the recording electrodes corresponding 10 Ihe 
electrograms shown in Figures ? and 3 Starr mdlcarc tiles of 
electrodes for programmed atrial stimulation LAA = lrf! .~lrial 
appendage: PY = pulmonary vein: RAA = right atrlal appendage. 
electmgrams (Fig. I). Two “nip&r leads WETC placed in the 
right atrium for programmed cathodal stimulation. The an- 
ode was placed in the abdominal wall. A venous cannula in 
the femoral vein was used to infuse normal saline solurton ar 
a rate of IO0 to 200 ml/h to replace fluids lost spontaneously 
and to iniect antiarrhyihmic drugs. 
Rle&ph~~f&gic .sludy. A&d elccrrograms fdrered al 
50 to 300 Hz and electrocardiographic (ECCI lead If were 
recorded simultaneously on an ink jet recorder lNihon 
Kohden. RIJ 2108) at paper speeds of IUU and 250 mm/s. 
Programmed stimulation was performed rrith a digital pro- 
grammable stimulator (M.E. Commercial. TAF 44OAr and a 
constant current source (Nihon Kohden. SSIWB). The 
stimuli used were a 2.ms rectangular pulse and twice the late 
diastolic threshold. 
The &ctitv r&rro~ period was determined by rhe 
extrastimulus technique at a basic pacing cycle length of 
300 ms. After every eight basic stimuli. an extrastimulus wub 
delivered in late diaatole. The coupling interval of extrastim- 
“Ii was shortened in 2.ms steps until a propagated atria1 
response was no longer produced. Determinarions were 
repeated to assure reproducibility of the data. The effective 
refractory period was dehned as rhe longest coupling interval 
that did no1 produce a propagated atrial response. 
of I50 m\ The time interval from the pacmg artifacl lo the 
elecnogram of 2 given left atrial elecrrcde was dewmined at 
;I paper speed of ?SO mm/s. 
c\rrrrri Pfctwr II (15 indrrced by h~rrst ntrirrl pncing at a cycle 
length of 100 to 13ll ms. Atrial flutier was defined as a regular 
atrial rhythm 31 a cycle len@h of I IO to I50 ms. Six 
consec”tiYc atrial cycle lengths were avcragcd to rcprcscnl 
rhc atria1 flutter cycle length in each dog. Rapid atrial odcing 
WI’, prrformed for 3 5 to demonstrate transiem entrainment 
f I.3.41. The pacing cycle length ua, shortened in S-m% steps 
uniil atria1 flutrer was interrupted or atrial fibrillation was 
induced. 
Experimental pmtocol. After atrial flutter wz mttmted. a 
period of 5 nin pas allowed for each dog to enwre that 
flutter WBF wwined. One of the four test drugs was injected 
lotravenously m eight dogs at the following doses: 2 m&of 
dwovramide over 3 min. 3 malta of tlecainide over 3 min. 
3 m$kg of propafcnonc over‘3 kin and 5 to IO &g of 
E-3031 “ver I nun. Propafenone was dissolved in 5% dex. 
trosc in uatcr and Ihc other drup were dissolved in normal 
saline solution Frve milliliters of vehtcle was injected over 
3 min during atrial flutter as a placebo test in three dogs. 
Drug injection VW discontinued if aoial flutter tcrminatcd 
during mnjcctlon. If atrial flutter was rustaincd until 5 min 
after the termination of drug injection. it was interrupted 
with burst a&l pacing. Arterial blood samples were ob- 
toined IO determute plasma drug concentrations. The elec- 
tmphpsiologic study was repeated and reinitiation of atrial 
Rutrer WIF attempted with use of burst atrial pacing. 
Analysis of data. The excitable gap was estimated as the 
dipcrcncc hetwccn the basic flutter cycle length and !ke 
\horteht pacing cycle length with transient entrainment but 
wthout intcrruphon of atrial Butter. This method was em 
ployed inrtead of the extrastimulus technique because with 
rhc latter technique. the stimulation site could affccl the 
determination of Ihe exucable gap (1). The effective refrac- 
tory period in the rcentranl circuit during atrial flutrer was 
then calculalcd hy subtracting the excitable gap from the 
basic flutter qcle length. Drug-induced change in the refrac- 
tory period in the reentrant circuit during atrral flutter was 
calcularcd by assuming that the tesl drugs prolonged the 
refractory period proportionally to that determined at a cycle 
length of 300 ms (131. 
Statirtics. Data are presented as mean values 2 SEM. 
Paired data were compared by using the paired I test. Dala 
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were compared among test groups by analysis of variance. 
Multiple comparisons were made by using lhe modified I test 
of Ryan 116). S~alislical Ggnilicance was set at p < 0.05. 
Results 
Electrophysiologic variables before drug injeclion (Table 
IL Because atrial flutkr wu termina[ed bv the lest drucs 
wirh conduction block occurrinu in Ihc low richt atrium 
around electrode 3 in all exceat IWO does. dataobiained fmm 
the slimulating eleclrode placed betw& electrodes 2 and 3 
(Fig. I) were used in the foliowine analvsis. In the control 
L . 
stale before Jruc iniectmn. the cvcle leneth of atrial Ruttcr _ ” 
ranted from 120 f 4 to 131 z 3 & in the four sludv crows 
(p = NSJ. A representative example of &w.iem e&&me’nt 
of atrial Rulteris shown in Figure 2. In the four study groups. 
the excitable gap ranged from 9 ? 2% to I I + 4% of the basic 
flutter cycle length. The effective refractory period in the 
recnlrant circuit during amal fluller ranged from 109 + 4 to 
I20 2 3 ms in lhe four study groups These values did not 




Figure 2. Delerminalion al the ex- 
cilahle gap with transienl entrain- 
mew In each panel. elewocardio- 
Eraphic lECGl lead II and aIrk 
eleclrograms recorded from EIX 
atria1 sites are arranged from top 10 
bourn. In thir pxiicular doz. the 
baw cycle lengih of alrial iutter 
was 140 ms llrfl panell. Transient 
enwainmenL withoul interruption al 
arrinl Rulter was seen at a pacing 
cycle length of I I5 rns (eenier panel). 
Further shonening of the pacing 
cycle length to I IO m interrupted 
atr~al Auucr Iright panell. The fifih 
pdciogarlifact(Sl from the left falled 
lo capture the atria and the canduc- 
lion did nor spread from ekclrodc 
4 10 3. Two nondriven atrial re- 
6PO”bes occurred. Con~ewenllY. 
&e excilable gap was esti&ed & 
25 ms (that is. 140 - I I5 m9 or I#% 
of the basic flutter cycle length. 
Effects of test drugs (Table 2). A representative example 
of the termination of atrial flutter with flecainide is shown in 
Figure 3. The respective doses injected and plasma ccvtcen- 
Irations of test drugs were as follows: 1.6 Y? 0.2 mg/kg and 
1.4 + 0.2 uelml for disoovramide. I .6 + 0.2 meike and 0.6 i 
0. I &nimlf& flecainide,‘~.Z ? 0.2 mgikg and I:3 g 0. I &ml 
fur orooafenone and 5.6 * I .O uelka and 16.2 2 4.3 &ml for 
E-4b3l: Changes in elec~roph&l&ic variables induced by 
the tesf drugs arc shown in Table 2. Atrial Rur~er was 
lerminated aiier prolongation of its cycle length by each test 
drug in all dogs except for Recainide and propafenonc in one 
dog each (Table 2). As expected, the increase in flutter cycle 
length was smaller with E-4031 than with Rccainide and 
pmpafenone Ip < 0.05). The increase in flutter cycle Length 
induced by disopyramide was intermediate between those 
induced by E-4031 and Recainide (p = NS). 
17re intrrrrse irtj%ilter cycle length did nor correlate wirh 
rlw iweccre br rhe ~ffer~iw rrfiucrory period determined at 
a cycle length of 300 ms. which tended 1o be smaller w&h 
Aecainide and propafenone than wirh disopyramide and 
E-4031 (p = NSI. In conlra~l. Ihe increase in Ruilcr cycle 
ERP- Terminillion Rcimlislion 
XT AF Of AF 0fAF 
Figure 3. Termmat~on of vtr~al 2 w,-e,:r- -h-y, a’- 
tturrer wrh Recainide trightl m rhe 
dog shown in Figure 2. The tracing 140 
on rhe left indicates atrial flutter 
200 
before drug injection. Flccainidc 3L--+A-L_ 
!crminated atria1 flutter after the 
flutter cycle length increased from 
140 ta 200 ms. Abbreviation ,md 
format IS in Figure 2. 4 ! ; ! -f, : I _ _ 
tionlime (kg. 4). which was maller with E-4031 than wth 
Recainide and propafenone Ip < 0.05). The increase in 
inter&d conduction time with disopyramide did not differ 
significantly from that with E-4031. 
Figure 4. Relation between changer in tlutlcr cycle length (FCLI 
and changes in interalrial conduction time MT). Thr ordinstr: 
indicates maximal flutter cycle length alter qcc!wn of test drug> 
and the ~bscissn shows the product of the cant~ol flutter cycle lenqh 
and the ratio of interatrial conduction time after drug injection tu 
lhat before drug injection. Open circles. PPW~~. squarer and closed 
cirrler indicate dara obraincd from dogs treated wth dkopywmds. 
Recainide. propafenone and E-4031. mxpsctivrl\ Th.rc \+in a 
positive correlation between the two variables. indiwtmp that the 
increase in flutter cycle tenglh was proportional IO lhar in interatrix 
conduction time. 
flutter cvcl; length ii, no; difkr from thnf just before 
termitutmn of atrial flutter (Fig. 51. indicating ihat the 
excitable pap \\a, abolished to terminate &‘ial flutter. The 
refractory period during atrial flutter after injection uf rhc 
other three drug wx, significantly smaller than the fluttsr 
cycle length hckxe terminauon of mini flutter (Fig. Jl. The 
evcitohie gap was increased by Recaintde (IO z 1% lo 2.8 f 
atrial flutter tERP-AFt lhatrhrd bars) afler mjectmn of test drugs. 
Rieht oanel. DdTcrence between the IWO vanabks shown in the lell 
5%. p < 0.011 and by propafenone 19 f 2% lo 31 f 4%. p < 
O.Ul) but not by disopyramide (II k 4% to 13 ? 2%. p = 
NS). These Cndings indicate rhal these three drugs inter- 
rupwd etrial lluctcr by suppressing conduction to a crucial 
point after which propagation of conduction became impos- 
sible. 
Reinitiation of atria1 flutter (Table 2). Atria flurter was 
reinitiated significantly more often with prupafenone and 
llccainide than with the other drugs (p < O.fMllL 
Discussion 
Major findings. The majur findings of the presenl sludy 
were that class IA. IC and 111 antiarrhyihmic drugs were all 
ekc~ive in terminating canine atrial flutter. as reported 
prevmusly (13.17-201. In addition. ihe increase in flulter 
cycle length induced by the drugs was proportional lo the 
increase in interatrial conduction time. indicating that the 
present canine model of atrial flutter corresponds to the ring 
model of reentry 011. E-4031 terminated atria1 Rut~er by 
aboiishing the excitable gap through greater prolongation of 
the refractory period relative IO a lesser stowing of conduc- 
t~on. Disopyramide. flecainide and prop&tone terminated 
atrial flutter by suppressing conduction to a crucial point 
beyond which propagation of canduclion became impossi- 
ble. Atrial flutter was reinitiated more often with Recainide 
and propafenone than with disopymmide and E-4031. 
Metbodologic considerations. Atrial flutter in the present 
canine model is due to reentry with an excitable gap (1.14). 
Our previous sludy (I) showed that the excilahle gap as 
determined by the extrastimulus technique was 21% of the 
basic flutter cycle Icngth. slightly greater than in the present 
study. This diffcrcnce might be due to the lower intensity of 
atrial stimulation in the present study and the difference in 
technique used to determine the excitable gap (that is. the 
extraslimulus tcchniquc in our previous study [I] and the 
entrainmenl technique in the prescnl sludy). The exclusion 
of dogs without a resetting of the atrial flutter cycle with 
extrastimuli from the analysis could have overestimated the 
excitable gap in the previous study I I I. The major limitation 
of the extrastimulus technique in determining the excitable 
gap is that the stimulation site relative to the reentmnt 
pathway could affect the determination (1.221. The clinical 
data from our previous study (I) showed that the entrain- 
ment zone. an indirect measure of the excitable gap in the 
present study. correlated with the greater value of the 
excitable gap determined with extrastimuli delivered at two 
atrial siles. Therefore. the method employed in the present 
study to determine the excitable gap scemed to be a suitable 
alternative to Ibc extraLtimuIus technique. However, the 
possible shortening of the refractory period along with the 
shortening of basic cycle length could overestimate the 
excitable gap at the basic Autter cycle length. 
The method used to de(ermirw Ike refrmrory pcriud ulso 
deserves wnmenl. It was difficult to determine the refrac- 
tory period at a cycle length of II0 to I50 ms (13). Basic 
atrial pacing with a shorter cycle length itself sometimes 
produced nondriven atrlal responses. as did extrastimuli 
with a shorter coupling interval. The effective refractory 
period in the reentrant circuit during atrial flutter was 
therefore determined by subu xting the w&able gap from 
the basic flutter cycle length. Another important method- 
ologic limitation is that the refractory period during atrial 
flutter after injection of drugs was calculated on the assump- 
lion that the change in the refractory period during atrial 
Autter was proportional to the change in the refractory 
period determined at a cycle length of300 ms. as in the study 
of Spinelli and Hoffman (13). 
This assumption. however. is not valid for every drug. 
For quinidinc and some class 111 drugs. the prolongation of 
refractoriness is rate dependent, resulting in an attenuation 
of the effect when decreasing the basic cycle length (23.24). 
a phenomena? of reverse use dependence (25). This reverse 
use dcpcndence of the effect on refractoriness, if present for 
disopyramidc and E-4031. might be neutralized to some 
extent by the possible overestimation of the present data 
pertaining to the excitable gap as a result of using the 
entrainment technique. In contrast, Recainide attenuated the 
ratedependent shortening of the aclion potential duration. 
resulting in a maximal drug-induced increase in refractori- 
ness at a shorter cycle length (24). The increase in the 
refractory period during atrial flutter at a cycle length of I79 
? II ms ITable 2) after injection of Recainide would be 
estimated at about 15% instead of 12.6% if the slope factor 
for the frequency-dependent effect of Recainide (that is, 
-20.3%/s shown in Table 3 of Ref. 24) were applied to our 
data. This small increase in the effecdve refractory ppricd 
during atrial flutter (12.6% to 15%) relative to the greater 
increase in conduction time seems unlikely to modify our 
conclusion regarding flecainide (Fig. 6). 
In previous studies, E-4031 was able to prevent induction 
of ventricular tachyarrhythmias in the dog heart with ntyo- 
cardial infarction (26) and acme myocardial &hernia (27). 
Induction of intraatrial reentry was also prevented by this 
drug in the isolated rabbit atrium (7). In the present study. 
atrial refractoriness was prolonged, as expected. However. 
interatrial conductton time at a pacing cycle length of IS0 ms 
was also prolonged slightly but significantly. Previous canine 
experiments showed that the class 111 drugs d-sotalol (17) 
and N-acetylprocainamide (18) prolonged inter&al conduc- 
tion time by 9% and 23%. respectively. at the pacing cycle 
length used in the present study. This prolongation might be 
explained by a decrease in the rate of rise in action potentials 
as a resull of depolarization occurring at less negative 
membrane potentials when the action potential duration is 
prolonged and the basic cycle length is shorter. This expla- 
nation needs lo be verified with the microelectrode tech- 
nique. 
The dose of E-4031 used in the present study was similar 
to that found (26) to be effective in suppressing canine 
ventricular tachycardia. Plasma concentrations of Aecainide 
(28) and propafenone (29) were within the effective ranges 
pcrimeler of ~upr~valvular alrinl tissue around the rncuspid 
~:+IvcI 131. The ~n~e,ri~rnrprhu~concluded that aholilion of 
E-D the cwtablc gp uas nol the rnechanrtm by which d-wralol 
terminated atri;ll lluuer. They used chronically instru- 
msntcd. corxioa~ dogs with Ruuer cycle lengths longer than 
rhwr used in Ihe preseol wdy. These d&erences mqhr 
conrnhulc LIJ rhe dilferem conclucionx reached rn the prew- 
ous \tudv I 131 and wrb. Addrtronally. their method 113) of 
derermining rhe refraclor): period deservr$ comment. They 
determmcd the rcfraaory penod by progressively mcreawg 
the Grcnglh of chtr~~timuli as the ~lnnuli bccamc more 
promarurc. The refractory period might have been longer if 
Figure 5. Schematic illuwation of the mcchamwn of mferruplmn 
rhey had uxd a lower output of extrastimuli with ir pules 
of reenuy. The flutter cycle length consists of Ihe effective refr&~ 
duration nxrw er than 3 to 1 rns. Consequently. the product 
tory period tERP) and lhe excitable gap (top lek panell. Fhib II OF &cnvt refracvxy period and conducrion velocn! might 
illustnted in the top right panel in a different way, wnh rhe elIeai\c have hem greater than they reporled 113). 
refractory period being indicated by a black lone. Bottom right Our data indicate rhal E-403 I produced greater prolunpa 
pnnel. Afier injccrlon ofanIlarrhglhmic drugs. reenrr) I$ mterrupled rron of refracrorine% relarive to the slowmg of conduction. 
when the &cove refractory period i? prolonged UERPI ~II ir 
r&lively greater magnitude rhan rhal of the 4owing of conduction 
lerdinp 10 &olrrion of the ercnable gap and termmauon of 
t CD) because the waw front meet the tissue m the refwrory atria1 llulter 1 Fig. 61. Slowing of conduction could neutralize 
period. This is the mechanism by which E-JOSI wwrupred atria1 lhe efficacy of prolonealion of Ihe refractory period in 
Ruller in the present surdy. When there IS grexter rlowop of tcrminatmg reentry. When the slowinS of conduction iQ 
conduction relative to pmloqation of the effective r&actor~ PC grsa~rr reMw lo the prolongaalion of rcfracmriness. as with 
nod. reentry is not terminaled (Q 1. Howcwr. if wnduclion i\ Rccaunde and propafenone. alrial flutter might not be leani- 
suppressed to a crucial point beyond which the prupagalion of 
conduction becomes impornible. reentry is interrupted I 0 I. l‘hi\ IS ni~tcd. although the Auucr cycle length 15 prolonged dromal- 
the mechanism by whrch drropynmide. RccrMde and nwpafenons really IFip. hr. Atrial flutler could be intsrr@ed by thcsu 
interrupted arrial Auuer in the prewnt study. drugs if conducuon was suppressed to a crucial poinl beyond 
u hi& rmpalsc spread became impossible <Fig. 61. Our d&a 
indicare thal for dixrpyrdmidr. suppressron of conducuon 
for suppressing a variety of clinical arrhythmias. However, war a crucial dererminanl for the lermination uf alrial flunsr. 
the plasma concentration of disopyramide was slighhrly IOUU This oh\crv;nion i\ no1 con~islem Gth dam froor prewous 
than the therapeutic range for humans @j. cqu~mcnlal t 17.181 and clinical (5) studie5 using clas5 IA 
Relalion between prolongation 01 relracioriness and rlon- dru_r\ and might possibly be due lo the slightly Iowcr plasma 
ing of conduction. Prolongation of reFractorine5s wrs sup- concentration of diweyramide in Ihe present study. 
Rested IO be critical for lcrminalion of reentry in clinical (51 Tiw irnp~rrniw of:Jw pmlr~agcdicr~r ofrrfkcrc~rbwss 1w5 
and experimental (17.18) surdies. In palients with suslained ,111, rowlMl;r,r~cl /Jr 01, r rcsrrlrs. Failure to prcvcnt reinilia- 
monomorphic ventricular tachycardia. it wa\ shown (51 Ihat bon of alrial Huller occurred more frequently in dogs treated 
less slowing of conduction and yeater prolongarron of with clw IC drugs than in those wealed with disopyramide 
refractoriners by procainamide abulishud reentry within the awl E-4nlI Uahlc 21. The Former drugs slowed conduction 
reentrant circuit. In an experimental study. Fcld ct al. I 17) more than ihcy Prolonged the refractory period. thereby 
concluded that prolongation of atrial refracloriness hy qui- incrrasing the ewtablc gap in comparison with the control 
nidine or d-slalol was the crucial dekrminant of termim- stale beforr drug injection. The mcrense in the excitable gap 
lion and prevention of reinihation of alrial Rutrcr in dog> porsihly srabiliLed a reentrant circuil. resulling in the more 
with intercaval crush. The same conclusion WBY dnrrn hy frcqoem reiniriatron of atrial Ruuer. as reported previously 
Okumura and Waldo (181. However. lho$e eupcrimenud ,171. This clfect could be a pushiblc mechanism of the 
studies did not relate changes in rcfrxlurine\s and cunduc- proarrh~thm~c cffccr of class IC drugs (301 if our data on 
tion to Ihe excitable gap. &itl flutter could he extrapolated to venlricular arrhyth- 
Spinclli and Hoffman (131 studied khe cffecrr of class 1 and mc;I~. 
class 111 antiarrhythmic drugs on afoal Butter in consciouQ Limitations. The presern rludy was limited for wcral 
dogs wilh a Y-shaped incision in Ihe right atrium and rslared reawnr I) Measurements of the excitable gap and refrac- 
changes in the refrac jry period and conduction lo rhe tory period dunng awin flutter were subject LO the mcthod- 
excitable gap. Atria1 Rutler was Lcrmina(cd with tc\t drug+. ologic problems discussed earlier. ?) Antiarrhythmic aaents 
hut the refraclorp perrod wa$ nor incrcnwd to the alriirl cwrt their effects preferentially in Ihe area of slow conduc- 
flutter cycle length even with d-soudol. The producl of twn in ~hc rccnoxnt circuit (31.31). We selected data ob- 
conduction velocity and effective refmctot\. period did not tainrd from rhe low right atrium brcaw atrial Autler wS 
become equal to the reentram pnlhway. whrch was the termrnalcd in the low right atrium in almosl all dogs. 
Changes m refwlormess in the particular area crucial for 
fermination of reentry might be different from those we 
analyzed. 3) We tested only a single doye of ,he drugs in each 
dog. Htgher dotes of test drugs mifiht produce differenl 
clectrophysiologlc changes. However. except for E-4031 our 
doqes yielded plasma concentrationF of drug5 equivalen, to 
or very close to the therapeutic r.wgccs for their clinical usage 
l8.28.29). E-4031 is slill an cxperimenfal drug and sufficient 
clinical data on its therapeutic plasma concentrations are 
lacking. 41 Although atnal flutter in our canine model has 
>omc rclcvancc ID clinical atrial flu:&. a, shown previously 
(IL the present rewlts should be extrapolated with caution 
to other models of arrhythmias and to humans. The present 
data. although limited for these reasons. might provide sane 
insight into the mechanisms by which antiarrhy,hmic drugs 
interrupt reentry. 
References 
2. Diwlori M. lnamu G. Verpra G.Cuamerro M. Del Fwero h. Furlanello 
F. Ewdence of k reentry crrcw m Ihe common ,ype of ubia, Ruaer in 
man Crrcula,“” IYB1:67 434-40 
1. Waldo AL, Hcnlhorn RW. Plumb VJ. MacLern WAH. DemonarJdon of 
,he mecharurm of lrunwn, cu,rarnmen, and rnlenuphon of ven,dcular 
brch)Lxdiu ui,h rapid alpal pacmg J Am Co,! Cardm, ,984:3:422-36. 
I Dkumura K. Henlhorn RW. Epslcin AE. Plumb VJ. Waldo AL Further 
ubrcrvubonr OR rransrrnr enr~inmrnr: imponmce of pscinY site and 
properder of Ihe cornpoued~ uflhc recnrry circuir Circu,u,ron ,Ya5:72: 
,.?Y,-307. 
5. Furukawa T. Rozanrki JJ. Moroe K. Goss&n Al. Liiler JW. Efficacy of 
procarnamide on wurriculur tachywdur: rekuiuu of pmlongainn of 
refruclormerr and rlowmg ofconduclion. Am Hear, J ,989:, ,8:70?-a. 
6. Sawadp K. Nomolo K. Hiruok;i M. tbcc,? ofa novel crass 3 anharrhyrh- 
mrc agent. E-403,. on ventrrculsr arrhydxmu~~abrrri. Jpn Circ J ,%8:5? 
YIY-2U. 
7. Adumy. H. H~raaka M. BRect5 of a now class III anriunhythmic uaen!. 
E-4031. on rccnrran, racbycardas rn rabbrl ngh, ,ur,um J Curdmvasc 
Pharmacd 19%15:976-82 
8. Moody F. Scheinmun MM. Dew 1. Uiropyramide. Intern Ann Med 
198?:%:137-43. 
9. Crorier Iti. lkrnm Il. Keneuly M. Levy L. Fiecaimde ate,a,e for 
~IIIIYLIIIOII of acute wpruventriculur tachycardia to LIOU< rhythm Am J 
Cardiol ,‘,R7:5Y:60,-Y. 
IO. Bern5 E. Rmkenbcrgr RL. Js;mu MK. Dougkerry AH. Jenkins hl. 
Nuccarelli GV. Efficacy aud sufcly of Recainrde xerule fur ama, why- 
cardra or kbri,,&n. Am J Car&a, ,987:59: 1337-41, 
I I. Coumel P. Leckrq IF. Arrayag P. Europcm rhpcrience with ,he and- 
arrhyrhmic efficacy of propafenane for rupravenrrr~ular and veu,r~cubu 
arrhvthmias. Am 1 Cardiol 19R4:54:Cl,DhD 
I?. Antman EM. Beamer AD. Canlillon C. McGowan N. Goldman L. 
triedman PL. Long-wrm orul pmpufeeune lhcrupy lor rupprcsrmn of 
r*fructory rymptomalrc alriul fibrillation and alrral Buucr. J Am Coil 
C.&o, IYRR:,2~,WS-I,. 
13 Spinelli W. Hoffman BF. Mccharurmr of rerminauon of rceurr;mr atriul 
arrhylhmrar by elars I and III anliarrhylhmw agems. Circ Aer 
ISbF7Y. 
llR9,65- 
14. lnoue H. To& I. Lihsra S. Susimolo T. Further obzrvaduns un 
enlra~nmen, ofalrral Rulrcr ,n ,he da! Am Hex, J ,%P:, 18’467-74. 
I5 Rorcnbluerh A. Garcia-Ramor J. Studies on flu,ler and hbnkauon. ,be 
mR”ence ofnnrbcial dbvacles on experimenlu, .,ri., Ruller. Am Hoar, J 
,%7:33.677-a,. 
16 Ryan TA. Significance tezb for mulliple ..xnparrson of propor6onr. 
variance. and olher srutisdcs. Psycho1 Bull 1%0:57:318-28. 
17. Fcld GK. Venkaierh N. Singh BN. Pharmacologrc cunuer6iou and 
suppression of crpcrimemal canine alrtal Au,ler drRermg eaeclr of 
dwtalo,. quinidine. and lidocame and srgnificance of changer in refruc 
iorinw and &wduc,ion C~rculalron ,%6:74:,!37~?04. 
18. Okumum K. Wuldo AL. Effecls of N-aEe,~lprocnlnamidean experimeu- 
bd &rrm, Rullcrrnd ulrra, electrophyrroloaic pmpnar in coureiour dogs 
wuh slerile pericardi,is: compsrisan with the cKcctr of quinidme. J Am 
Coil Cardiol 1987:%133!-8. 
23. Taude PM. Bjomslad H. Yana T. Refsum H. ka,edependent clals 111 
anliarrhylhmz &on. nepalive chrouolropy. and poritivr inolropy of a 
novel I* bkkingdrue. UK68798: prrlenr rnguiueuprg bur noeffecr in rat 
myocnrdium. I Curdiovarc Pharmacol 1990:16:401-IO. 
24. W;mng Z. F’ellelier C. Talajic hf. Natlel S. Eaecls of Rcainide and 
quiuidine on humun ulrial u&m porenhu,~: rule ofraredependenrc and 
comparison with guinea pig. rubbi,.md cMg twuc~. Circulation ,wO:BZ: 
274-81. 
25. Haudcghem LM. Sny&rr DJ. Class 111 undarrhyrhmic bYems have a 101 
of pownrial but a lung wuy 10 go: reduced e&c,ivenen and daugrrr of 
rwerse use dependence. C~rculabon 1990:81:h%-90. 
26. Kaio H. Ogawa S. Furuno 1. et al. FJecrrophysiologic effecrr of E-403,. 
P cluss Ill an,ianhy,hmic uaen,. on reentruu, ven,ricular arrhyrhmrar in a 
canine 7duyold myocurdiu, infarcdon model. J Phsrmaco, Exp The, 
lwk25331rJ77-82. 
27. Lynch JJ. Heaney LA. Wallace AA. Gehre, JR. Selnick HG. Srein RB. 
Suppression of ,elhu, ischemic venrrfcu,ar arrhylhmiar by ,hC class 11, 
a@ E-401, in II canme mcdrl of previous myocardial infarcdau. 
I Cardiovasc Pharmacul 1990:15:74d-75. 
1. Duff HJ. Rodcn DM. Maffuccr RJ. el al. Suppression of reddun 
ventricular arrhythmias by twice daily dosing wilh Recainide. Am I 
Curdiol ,98,:48:,,334fl, 
2Y Naccure,la F. Brdcchelb D. PuJmrcn M. Maaherini 8. Ambrwoni E. 
Propafenone for refraclory venbiculsrarrhyrhmius: sorreladon wkh drug 
plasma levels duriuY Iong-wu, ,rea,meu,. Am J Cardiol ,984:54: IfMa-,l. 
30. Rae Al’. Kay HR. Horowirr LN. Spblmau SR. Greenspan AM. Pmsr. 
rhythmic efleclr of an,iarrhy,hmic druYr in patients wth malignan, 
ventricular arrhythmias evaluaed by elewophy~iologic testing. J Am 
Coil Cardial 1988:12:131-9. 
31. Kuy GN. Epstein AE. Plumb VJ. Preferential oRect of pmainamide an 
[he reenlrun, circui, of ventricular Uchycardra. J Am Co,, Cardm, 
,%Y:,432-%. 
32 Okumura K. HondrT. Nirbiazmri K. Huyasaki K. Facllllarronoflocaliled 
conduction block wirh prvcuiuumide during eutruinmenr ui auUained 
vrnlrrcular lachycardra. A” Hear, J ,YaY.1,8.630-2. 
